BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10582140)

  • 1. The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer.
    Kelly K
    Ann Oncol; 1999; 10 Suppl 5():S53-6. PubMed ID: 10582140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.
    Gridelli C; Cigolari S; Gallo C; Manzione L; Ianniello GP; Frontini L; Ferraù F; Robbiati SF; Adamo V; Gasparini G; Novello S; Perrone F;
    Lung Cancer; 2001; 31(2-3):277-84. PubMed ID: 11165408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
    Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
    Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
    Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
    Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
    Lilenbaum R; Cano R; Schwartz M; Siegel L; Lutzky J; Lewis M; Krill E; Barreras L; Davila E
    Cancer; 2000 Feb; 88(3):557-62. PubMed ID: 10649247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
    Tennvall GR; Fernberg JO
    Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
    Metro G; Cappuzzo F; Finocchiaro G; Toschi L; Crinò L
    Ann Oncol; 2006 May; 17 Suppl 5():v37-46. PubMed ID: 16807461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
    Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
    Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.
    Quoix E; Breton JL; Ducoloné A; Mennecier B; Depierre A; Lemarié E; Moro-Sibilot D; Germa C; Neidhardt AC
    Lung Cancer; 2005 Mar; 47(3):405-12. PubMed ID: 15713524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
    Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
    Bhatia S; Hanna N; Ansari R; Pletcher W; Einhorn L; Ng E; Sandler A
    Lung Cancer; 2002 Oct; 38(1):73-7. PubMed ID: 12367796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
    Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
    Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
    Sandler AB; Nemunaitis J; Denham C; von Pawel J; Cormier Y; Gatzemeier U; Mattson K; Manegold C; Palmer MC; Gregor A; Nguyen B; Niyikiza C; Einhorn LH
    J Clin Oncol; 2000 Jan; 18(1):122-30. PubMed ID: 10623702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.